RxDoctor Payments Data

Edward Gill, MD

Cardiovascular Disease · Aurora, CONPI 1518046275

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $71,350 of the $96,170 with a category attached, or 74.2%. Philips North America LLC accounts for 95.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $23,930 and has fallen 55.0% since, to $10,770 in 2025. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$96,170in general payments, 2019–2025

Across 155 payments — averaging $620.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$92K
  • Edwards Lifesciences$3K
  • Abbott$306
  • Amgen$238
  • Boston Scientific$210
  • Kaneka Medical America LLC$210
  • plus $459 from 6 others

What the payments were for

  • Speaking & faculty fees$71,35074%
  • Travel & lodging$20,42121%
  • Food & beverage$4,3995%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$96,170 in reported general payments places this provider in the 95th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$129,347
Medicare patients
3,266
Services billed
5,981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten32$247,664
EliquisApixaban37$55,796
EntrestoSacubitril/Valsartan30$46,240
JardianceEmpagliflozin20$33,247
Metoprolol Succinate150$2,914
Bumetanide17$2,068
Rosuvastatin Calcium86$1,938
Ezetimibe25$646
Verapamil ErVerapamil Hcl12$642
Atorvastatin Calcium67$586
Torsemide16$506
Losartan Potassium51$406
Spironolactone38$373
Metoprolol Tartrate49$355
Lisinopril37$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$77$247,66432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →